A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events

Research output: Contribution to journalComment/debatepeer-review

Abstract

Finding biomarkers for predicting anti-tumor responses and immune-related adverse events (irAEs) with immune checkpoint therapy remains a challenge. Lozano et al. have developed a composite biomarker score that includes the frequency of effector-memory CD4 T cells and TCR clonality of CD4 T cells in peripheral blood as a potentially predictive biomarker of irAEs.

Original languageEnglish (US)
Pages (from-to)249-251
Number of pages3
JournalCancer cell
Volume40
Issue number3
DOIs
StatePublished - Mar 14 2022

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint

Dive into the research topics of 'A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events'. Together they form a unique fingerprint.

Cite this